When was FORMEL Skin founded?

FORMEL Skin was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is FORMEL Skin located?

FORMEL Skin is headquartered in Berlin, Germany.

Which legal entities is FORMEL Skin associated with?

FORMEL Skin is associated with Formel Skin Derma GmbH and 2 others.

How many employees does FORMEL Skin have?

As of Aug 31, 2026, the latest employee count at FORMEL Skin is 86.

Is FORMEL Skin a funded company?

FORMEL Skin is a funded company, having raised a total of $39.7M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 10, 2021.

When was the latest funding round of FORMEL Skin?

FORMEL Skin's latest funding was a $***** Series A round on Dec 20, 2021, with participation from 5 investors. Its primary sector is Dermatology. Globally, the Dermatology sector has seen $696M in funding in 2026 to date.

Where does FORMEL Skin rank among its competitors?

FORMEL Skin ranks 321st amongst 2639 active competitors, of which 869 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of FORMEL Skin?

FORMEL Skin's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Syndax. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

FORMEL Skin - 2026 Company Profile, Team, Funding, Competitors & Financials

FORMEL Skin is an acquired company based in Berlin (Germany), founded in 2020 by Anton Kononov and Florian Semler. It operates as a Manufacturer of dermatological skin care products. FORMEL Skin has raised $39.7M in funding from investors like Singular, Cherry Ventures and Heartcore Capital. The company has 2639 active competitors, including 869 funded and 633 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Syndax.

Company Details

Website: www.formelskin.de/
Social
Email ID: *****@formelskin.de
Phone Number: +49 **********

Key Metrics

Founded Year

2020

Location

Berlin, Germany

Stage

Acquired

Total Funding

$39.7M in 2 rounds

Latest Funding Round

Series A, Dec 20, 2021, $*****

Investors

Singular & 10 more

Ranked

321^st among 2639 active competitors

Employee Count

86 as on Aug 31, 2026

Similar Companies

LEO Pharma & 200 more

Exit Details

Acquired by Manual (Dec 05, 2025)

View FORMEL Skin's full profile

FORMEL Skin is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count
Formel Skin Derma GmbH CIN: F1103_HRB216314B , Germany, Active	Mar 30, 2020	-	-
TrueSkin GmbH CIN: HRB212398 , Germany, Active	Nov 20, 2019	-	-
Formel Skin Derma GmbH CIN: HRB216314 , Germany, Active	Mar 29, 2020	-	-

FORMEL Skin got acquired by Manual on Dec 05, 2025.

Click here to take a look at FORMEL Skin's acquisition in detail

FORMEL Skin has raised a total funding of $39.7M over 2 rounds. Its first funding round was on Jan 10, 2021. Its latest funding round was a Series A round on Dec 20, 2021 for $*****. 5 investors participated in its latest round. FORMEL Skin has 8 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of FORMEL Skin:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 20, 2021	9483178	Series A	4970289	7240920	6558938	6977113
Jan 10, 2021	4951056	Series A	1065142	4725351	Cherry Ventures & 2 more	7060363

Access funding benchmarks and valuations. Sign up today!

View details of FORMEL Skin's funding rounds and investors

The founders of FORMEL Skin are Anton Kononov and Florian Semler.

Here are the details of FORMEL Skin's key team members:

Anton Kononov: Co-Founder of FORMEL Skin. They are also an angel investor in 1 startup and serve on the board of 1 company.
Florian Semler: Co-Founder of FORMEL Skin. They serve on the board of 1 company.

FORMEL Skin's Board of Directors

FORMEL Skin's board has 2 active members. Anton Kononov and Florian Semler are part of team.

Here is the list of FORMEL Skin's board of directors:

Name	Type	Representing	Status	Duration
Anton Kononov	Team	-	Current	6y 6m
ejpsqrr	Team	-	Past	6y 1m

View details of FORMEL Skin's Founder profiles and Board Members

FORMEL Skin's employee count trend

FORMEL Skin has 86 employees as of Aug 26. Here is FORMEL Skin's employee count trend over the years:

Uncover FORMEL Skin's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of FORMEL Skin include Jazz Pharmaceuticals, Sana Biotechnology and Syndax. Here is the list of Top 10 competitors of FORMEL Skin, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
4th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
6th	LEO Pharma 1908, Copenhagen (Denmark), Late Stage	Developer of drugs for treating dermatology diseases	$560M	Nordic Capital	71/100
7th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
8th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
9th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
10th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	70/100
321st	FORMEL Skin 2020, Berlin (Germany), Acquired	Manufacturer of dermatological skin care products	$39.7M	Heartcore Capital, Singular & 9 others	54/100